Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro does not specifically target or remove cellulite. Weight loss achieved through tirzepatide may reduce the visibility of cellulite in some people, simply because less subcutaneous fat beneath the skin can soften its appearance, but there is no clinical evidence that Mounjaro acts on cellulite directly. The question of whether it gets rid of it entirely is one our prescribers hear most weeks, and the honest answer is more nuanced than the headlines suggest. Mounjaro is a prescription-only medicine licensed in the UK for weight management in adults who meet specific clinical criteria — a prescriber assesses suitability individually, not a fixed checklist applied to everyone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Cellulite appears when subcutaneous fat pushes through a mesh of fibrous connective-tissue bands that run between the skin and the muscle underneath. The dimpled effect depends on the thickness and tension of those bands, skin elasticity, and genetics, not just how much fat sits there. This is why people with very little body fat can have prominent cellulite, and why people who lose significant weight sometimes find it barely changes.
The idea that Mounjaro could specifically eliminate cellulite has spread partly because the weight-loss results in clinical trials are striking. The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at the 15 mg dose over 72 weeks in adults without diabetes. That scale of change is real, and it does affect how the body looks. But the trial measured weight and metabolic markers, not skin texture, not cellulite scores. There is no published clinical evidence that tirzepatide acts on the connective-tissue structure responsible for cellulite. Believing it does is understandable, but it sets expectations the medicine was never designed to meet.
You can read more about tirzepatide and cellulite in our dedicated overview, which goes deeper on the skin-structure question.
Significant fat loss does change the body's contours, and for some people that shift reduces the visibility of cellulite, particularly in areas where the subcutaneous fat layer was substantial. Less pressure from beneath means the connective tissue bands are pulled less taut, and the dimpling may look less pronounced. That is not the same as the cellulite being gone; the underlying structure remains.
There are other factors at play too. Muscle mass matters: the way the body responds to tirzepatide over time can include some loss of lean mass alongside fat, especially without adequate protein intake and resistance activity. Maintaining muscle tends to keep skin looking firmer, so the visible result of weight loss varies considerably between people depending on their diet quality and exercise habits during treatment.
Skin elasticity also changes with age and with the speed of fat loss. Rapid changes in body composition sometimes make skin laxity more noticeable, which can temporarily make texture look different, not always in the way people hope. This is not a reason to avoid treatment; it is context that helps set realistic expectations.
If you are considering Mounjaro primarily because of cellulite concerns, it is worth thinking honestly about whether significant weight loss is the right goal for you. The clinical eligibility thresholds exist precisely because these medicines carry real pharmacological effects and are not suited to cosmetic use.
The MHRA has been explicit: GLP-1 medicines, including tirzepatide (Mounjaro), are not assessed or licensed for quick or cosmetic weight loss. That position directly addresses the kind of marketing sometimes seen online suggesting these medicines are a shortcut to a smoother silhouette.
Mounjaro is a prescription-only medicine reviewed by the NHS for adults with a BMI of 30 or above, or 27 or above alongside a relevant weight-related condition such as hypertension, dyslipidaemia, type 2 diabetes, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber assesses the complete clinical picture, not just the number on the scale.
The cost context is straightforward too: private treatment involves a transparent price that covers the clinical assessment and prescription, not just the medicine itself. You can find a clear breakdown of what that involves on our Mounjaro cost page. For most people, the decision belongs in a conversation about metabolic health and long-term weight management, not in a search for a cellulite fix.
There is no treatment, whether pharmaceutical or cosmetic, with strong evidence for permanently eliminating cellulite. Some physical treatments (radiofrequency, subcision, acoustic wave therapy) have modest evidence for temporary improvement. A consistent resistance-exercise programme that builds muscle beneath the fat layer tends to produce the most durable visible improvement alongside weight loss, and it also protects lean mass during GLP-1 treatment, which is a genuine benefit.
If you do qualify for Mounjaro on clinical grounds and your BMI and health picture make it appropriate, the weight-management benefits are well-evidenced and extend well beyond appearance: metabolic markers, blood pressure, cardiovascular risk, and quality of life all feature in the trial data. You can explore the broader evidence at our Mounjaro overview or look at whether Mounjaro specifically affects abdominal fat, which is a related question with a more evidence-backed answer.
A consultation with a prescriber is the right starting point, not because it is a sales step, but because it is the only way to know whether treatment is appropriate for you, and to have realistic goals agreed at the outset. Speak to our prescribers through a free consultation if you would like that conversation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.